Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more
Pmv Pharmaceuticals Inc - Asset Resilience Ratio
Pmv Pharmaceuticals Inc (PMVP) has an Asset Resilience Ratio of 64.31% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Pmv Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Pmv Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $74.96 Million | 64.31% |
| Total Liquid Assets | $74.96 Million | 64.31% |
Asset Resilience Insights
- Very High Liquidity: Pmv Pharmaceuticals Inc maintains exceptional liquid asset reserves at 64.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pmv Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Pmv Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Pmv Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.31% | $74.96 Million | $116.56 Million | -2.91pp |
| 2024-12-31 | 67.22% | $128.58 Million | $191.29 Million | +1.64pp |
| 2023-12-31 | 65.58% | $165.35 Million | $252.15 Million | +16.46pp |
| 2022-12-31 | 49.11% | $132.76 Million | $270.31 Million | +11.51pp |
| 2021-12-31 | 37.61% | $124.70 Million | $331.57 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $365.53 Million | -- |
| 2019-12-31 | 27.38% | $28.21 Million | $103.03 Million | -22.42pp |
| 2018-12-31 | 49.80% | $31.60 Million | $63.46 Million | -- |